Log in to search using one of your social media accounts:

 

Merck brings customers closer to gene therapy product commercialization
Merck today announced that its Carlsbad, California-based manufacturing facility for the production of BioReliance® viral and gene therapy products has completed both a U.S. Food & Drug Administration (FDA) Pre-License inspection and a European Medicines Agency (EMA) Marketing Authorization Application inspection. (Source: World Pharma News)
Source: World Pharma News - October 19, 2017 Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news

AstraZeneca ’s Faslodex receives CHMP opinion for advanced breast cancer treatment
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for AstraZeneca ’s Faslodex (fulvestrant) to treat hormone receptor-positive (HR+) advanced breast cancer in combination wi… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 16, 2017 Category: Pharmaceuticals Source Type: news

Shire ’s lyophilised Oncaspar receives positive CHMP opinion for ALL in Europe
Irish-headquartered biopharmaceutical company Shire ’s lyophilised Oncaspar (pegaspargase) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for patients with acute ly… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 15, 2017 Category: Pharmaceuticals Source Type: news

Milan hopes to gain from Barcelona's pain in race for EU drugs agency
MILAN (Reuters) - Milan is hoping that Spain's Catalonia crisis will give the Italian city a boost in getting to host the European Medicines Agency (EMA), the European Union agency quitting London because of Brexit. (Source: Reuters: Health)
Source: Reuters: Health - October 13, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Roche's Alecensa wins EU panel's nod against mutated lung cancer
ZURICH (Reuters) - Swiss drugmaker Roche's Alecensa has been recommended for approval in Europe as a first-line treatment for mutated lung cancer, a key European Medicines Agency (ESA) experts panel said on Friday. (Source: Reuters: Health)
Source: Reuters: Health - October 13, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

EMA accepts marketing application for Imfinzi to treat NSCLC patients
The European Medicines Agency (EMA) has accepted a marketing authorisation application (MAA) for AstraZeneca and MedImmune ’s Imfinzi (durvalumab) to treat patients with locally advanced, unresectable non-small-cell lung cancer (NSCLC). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 9, 2017 Category: Pharmaceuticals Source Type: news

European Medicines Agency moves to plug staffing gap after Brexit
London-based EU drugs regulator in £32m bid for temporary staff after it leaves UK capital (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - October 6, 2017 Category: Pharmaceuticals Source Type: news

Many new cancer drugs show 'no clear benefit', argues review
Conclusion Most of us assume that when a drug has been approved by a regulator for use, that means it has been shown to work. This study suggests that is not necessarily the case, or that even if it works they might not make a meaningful difference. The absence of evidence about the two outcomes that matter most to patients and their families – how long they will live, and how good their quality of life will be during that time – from half of the cancer drugs approved during a five-year period, is worrying. Patients cannot be expected to make informed decisions about which treatments to take, without good quali...
Source: NHS News Feed - October 5, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

Over half of new cancer drugs 'show no benefits' for survival or wellbeing
Of 48 cancer drugs approved between 2009-2013, 57% of uses showed no benefits and some benefits were ‘clinically meaningless’, says BMJ studyMost cancer drugs that have recently arrived on the market have come with little evidence that they boost the survival or wellbeing of patients, research reveals.Forty-eight cancer drugs were approved by the European Medicines Agency between 2009 and 2013 for use as treatments in 68 different situations.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - October 5, 2017 Category: Science Authors: Nicola Davis Tags: Pharmaceuticals industry Cancer research Drugs Regulators Medical research Drugs policy Health policy Life expectancy Business Medicine Science UK news Source Type: news

The costly cancer drugs that don't help patients
Researchers found this was true of 57 per cent of treatments approved by the European Medicines Agency between 2009 and 2013. Many were provided in Britain through the Cancer Drugs Fund. (Source: the Mail online | Health)
Source: the Mail online | Health - October 4, 2017 Category: Consumer Health News Source Type: news

Study questions European approval process for cancer drugs
A new study finds that only about half of the cancer drug approvals by the European Medicines Agency in the last few years helped patients live longer or improved their lives. (Source: ABC News: Health)
Source: ABC News: Health - October 4, 2017 Category: Consumer Health News Tags: Health Source Type: news

Spoils of Brexit: EU cities race to get EU agencies from UK
Competition to host the European Medicines Agency and the European Banking Authority heats up this week with many EU nations still confident they can land one of the prestigious organizations (Source: ABC News: Health)
Source: ABC News: Health - October 3, 2017 Category: Consumer Health News Tags: Health Source Type: news

European panel backs Janssen's psoriasis drug
(Reuters) - A European Medicines Agency (EMA) panel recommended the approval of Johnson& Johnson unit Janssen's drug, guselkumab, for the treatment of plaque psoriasis in adults. (Source: Reuters: Health)
Source: Reuters: Health - September 15, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

GSK ’s triple-med COPD inhaler wins recommendation for approval in EU
GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) said today that a European Medicines Agency panel recommended marketing authorization for the Trelegy Ellipta triple-combination inhaler for adults with COPD. The device uses fluticasone furoate, umeclidinium and vilanterol to help adults with COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist. It’s also the first once-daily single inhaler triple therapy to win a positive opinion by the Committee for Medicinal Products for Human Use, the companies reported. Get the full story at our sister...
Source: Mass Device - September 15, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Regulatory/Compliance Respiratory Wall Street Beat GlaxoSmithKline plc Innoviva Source Type: news

Tesaro's ovarian cancer drug gets EU agency backing
(Reuters) - A European Medicines Agency (EMA) panel recommended the approval of Tesaro Inc's key drug, niraparib, for the treatment of recurrent ovarian cancer. (Source: Reuters: Health)
Source: Reuters: Health - September 15, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

GSK's three-in-one inhaler gets positive opinion from EU agency
(Reuters) - GlaxoSmithKline said on Friday that a European Medicines Agency (EMA) panel has recommended the company's three-in-one inhaled lung drug. (Source: Reuters: Health)
Source: Reuters: Health - September 15, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

EMA accepts Pfizer ’s bosulif Type II Variation application for Ph+ CML
The European Medicines Agency (EMA) has approved for review a Type II Variation application for the use of Pfizer ’s bosulif (bosutinib) to treat patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 30, 2017 Category: Pharmaceuticals Source Type: news

FDA, EMA Strengthen Drug Inspection Cooperation FDA, EMA Strengthen Drug Inspection Cooperation
A new confidentiality agreement allows the FDA to share full drug inspection reports with the European Commission and the European Medicines Agency.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 25, 2017 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

Drug blocked by European regulators improves quality of life for MS patients
A study by researchers at the Queen Mary University of London has found that a drug blocked by European regulators can improve the quality of life for people with multiple sclerosis. The team of researchers reached this conclusion after uncovering previously unpublished clinical trial data from the European Medicines Agency. The European Commission is currently considering whether it will reverse its decision to deny a license for the oral formulation of the drug, cladribine. Get the full story at our sister site, Drug Delivery Business News. The post Drug blocked by European regulators improves quality of life f...
Source: Mass Device - August 18, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Pharmaceuticals Regulatory/Compliance queenmaryuniversityoflondon Source Type: news

Positive CHMP Assessment for Haselmeier Pergoveris ® Pen
The new Pergoveris ® Pen by Haselmeier has received a positive assessment by Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 16, 2017 Category: Pharmaceuticals Source Type: news

Brexit relocation of EU medicines regulator 'will hit UK researchers hard'
Amsterdam says in its bid to house the EMA that two of Britain ’s top research agencies would lose much of their businessTwo of the UK ’s foremost research organisations will lose much of their business to Amsterdam if the city is successful in securing the relocation of the EU’s medicines regulator, the Netherlands’ formal bid for the prized agency claims.Amsterdam, which has been tipped as an early favourite to secure the European Medicines Agency (EMA), says in its application submitted to the European commission that losing the agency will prove a double blow to London when Brexit forces its mov...
Source: Guardian Unlimited Science - August 8, 2017 Category: Science Authors: Daniel Boffey in Brussels Tags: Brexit Netherlands London Medical research Europe European Union Foreign policy Politics Science UK news Source Type: news

Kite Pharma submits MAA for axicabtagene ciloleucel in Europe
US-based cell therapy company Kite Pharma has filed a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for axicabtagene ciloleucel. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 1, 2017 Category: Pharmaceuticals Source Type: news

ECDC/EFSA/EMA Second Joint Report on the Integrated Analysis of the Consumption of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Bacteria from Humans and Food-Producing Animals
European Union, European Centre for Disease Prevention and Control. 07/27/2017 This 135-page document is the second joint report from the European Centre for Disease Prevention and Control (ECDC), European Food Safety Authority (EFSA), and European Medicines Agency (EMA), on the integrated analysis of antimicrobial consumption (AMC) and antimicrobial resistance (AMR) in bacteria from humans and food-producing animals. It addresses data obtained by the Agencies'European Union-wide surveillance networks for 2013-2015. AMC in both sectors was compared at country and European levels, and substantial variations between countrie...
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - July 28, 2017 Category: International Medicine & Public Health Authors: The U.S. National Library of Medicine Source Type: news

Eisai seeks marketing authorisation for lenvatinib from EMA
Eisai has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for first-line use of lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 27, 2017 Category: Pharmaceuticals Source Type: news

EU report: More evidence on link between antibiotic use and antibiotic resistance
(European Centre for Disease Prevention and Control (ECDC)) The European Food Safety Authority, the European Medicines Agency and the European Centre for Disease Prevention and Control are concerned about the impact of use of antibiotics on the increase in antibiotic-resistant bacteria. The report presents new data on antibiotic consumption and antibiotic resistance and reflects improved surveillance across Europe. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 27, 2017 Category: Biology Source Type: news

Janssen receives EMA committee recommendation to market Symtuza for HIV
Janssen-Cilag International (Janssen) has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorisation for Symtuza for the treatment of HIV. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 24, 2017 Category: Pharmaceuticals Source Type: news

Tocagen Receives European Medicines Agency Priority Medicines (PRIME) Designation for Toca 511 in High Grade Glioma
SAN DIEGO, July 24, 2017 -- (Healthcare Sales & Marketing Network) -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced the European Medicines Agency (EMA) has granted Toca 511 (vocimagene amiretrorepvec... Biopharmaceuticals, Oncology, Regulatory Tocagen, Toca 511, glioma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 24, 2017 Category: Pharmaceuticals Source Type: news

EMA ’s CHMP recommends Merck and Pfizer's cancer drug avelumab for approval
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Merck and Pfizer's avelumab (BAVENCIO) as a monotherapy to treat adult patients with metastatic Mer … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 23, 2017 Category: Pharmaceuticals Source Type: news

Roche's Tecentriq receives positive opinion from EU medicines agency
ZURICH (Reuters) - A European Medicines Agency (EMA) panel said on Friday it has recommended Roche's immunotherapy Tecentriq as a treatment for advanced bladder and lung cancer, setting the stage for European Commission approval this year. (Source: Reuters: Health)
Source: Reuters: Health - July 22, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

EMA Final Opinion Confirms Gadolinium Restrictions EMA Final Opinion Confirms Gadolinium Restrictions
The European Medicines Agency is restricting the use of some linear gadolinium agents used in MRI scans and suspending authorization of others.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 21, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

EU Panel Recommends Dupilumab (Dupixent) for Eczema EU Panel Recommends Dupilumab (Dupixent) for Eczema
A committee of the European Medicines Agency has recommended marketing authorization for dupilumab (Dupixent) for the treatment of moderate to severe atopic dermatitis in adults who are candidates for systemic therapy.International Approvals (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - July 21, 2017 Category: Allergy & Immunology Tags: Dermatology News Alert Source Type: news

Once-Daily Symtuza Wins CHMP Approval for HIV Once-Daily Symtuza Wins CHMP Approval for HIV
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the once-daily oral HIV combination therapy Symtuza for marketing approval.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 21, 2017 Category: Consumer Health News Tags: HIV/AIDS News Alert Source Type: news

CHMP Says No to Antipsychotic for Acute Schizophrenia CHMP Says No to Antipsychotic for Acute Schizophrenia
The European Medicines Agency's committee has recommended against approval of the antipsychotic iloperidone (Fanaptum, Vanda Pharmaceuticals Ltd) as a treatment for acute schizophrenia in adults.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 21, 2017 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum(TM) for the Treatment of Schizophrenia
WASHINGTON, July 21, 2017 -- (Healthcare Sales & Marketing Network) -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that the European Medicines Agency's Committee for Medicinal Product for Human Use (CHMP) has adopted a negative opin... Biopharmaceuticals, Regulatory Vanda Pharmaceuticals, Fanaptum, iloperidone, schizophrenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 21, 2017 Category: Pharmaceuticals Source Type: news

EU medicines agency recommends approval of Novartis leukaemia drug Rydapt
ZURICH (Reuters) - A European Medicines Agency (EMA) panel recommended on Friday approval of a new Novartis drug to be used against a tough-to-cure form of blood cancer as the Swiss drugmaker makes headway on refreshing its oncology portfolio. (Source: Reuters: Health)
Source: Reuters: Health - July 21, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

EU watchdog: EU drug agency may be too cozy with industry
(Reuters) – The European Medicines Agency (EMA), eager to accelerate access to promising new drugs, may be getting too cozy with the pharmaceutical companies it regulates. That is the concern of the watchdog charged with overseeing administrative irregularities in the European Union, which is launching a strategic inquiry to see if early-stage interactions with firms could influence agency approval decisions. Get the full story at our sister site, Drug Delivery Business News. The post EU watchdog: EU drug agency may be too cozy with industry appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 19, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Pharmaceuticals Regulatory/Compliance Wall Street Beat Source Type: news

EU watchdog concerned drug agency EMA may be too close to companies
LONDON (Reuters) - The European Medicines Agency (EMA), eager to accelerate access to promising new drugs, may be getting too cosy with the pharmaceutical companies it regulates. (Source: Reuters: Health)
Source: Reuters: Health - July 19, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA collaborates to promote safety, quality in clinical trials done in India
Leslie Ball, M.D., Assistant Commissioner of International Programs (left), and Elizabeth Wiley, M.D., J.D., M.P.H., AAAS Science and Technology Policy Fellow, share some highlights from their recent training trip to India. By Leslie Ball, M.D., Letitia Robinson, Ph.D., R.N, and Elizabeth Wiley, M.D., J.D., M.P.H. After more than 16 hours of travel, we touch down in Mumbai late in the evening and are greeted by a wave of heat and humidity as we exit the airport terminal. As we drive from the airport to the hotel, the vast Mumbai skyline is striking. India is home to 17% of the world’s population but accounts for abou...
Source: Mass Device - July 18, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Blog FDA Voice Source Type: news

Amgen Submits Regulatory Applications In US And Europe To Include Overall Survival Data In KYPROLIS ® (Carfilzomib) Label
Data Showed KYPROLIS and Dexamethasone Reduced the Risk of Death by 21 Percent and Increased Overall Survival by 7.6 Months Compared to Velcade® (Bortezomib) and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients THOUSAND OAKS, Calif., July 14, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) and a variation to the marketing application to the European Medicines Agency (EMA) to include overall survival (OS) data from the Phase 3 head-to-head ENDEAVOR trial in the product information fo...
Source: Amgen News Release - July 14, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

EMA validates Gilead Sciences ’ marketing application for BIC/FTC/TAF combination
US biopharmaceutical company Gilead Sciences ’ marketing authorisation application (MAA) for a fixed-dose drug combination to treat HIV-1 infection in adults has been fully validated and is currently under evaluation by the European Medicines Agency (… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 13, 2017 Category: Pharmaceuticals Source Type: news

IPM's dapivirine vaginal ring now under review by European Medicines Agency
(Burness) The nonprofit International Partnership for Microbicides (IPM) is pleased to announce that its application for the monthly dapivirine vaginal ring, designed to reduce the risk of HIV-1 infection via vaginal intercourse in HIV-negative women in combination with safer sex practices, has been validated and is now under review by the European Medicines Agency (EMA). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 13, 2017 Category: International Medicine & Public Health Source Type: news

EUSA Pharma Receives Positive CHMP Opinion for Tivozanib
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of FOTIVDA ® (tivozanib) for the management of adult patients with advanced renal cell carcinoma (RCC). EUSA's marketing authorisation application included data from the TiVO-1 pivotal study, which included over 500 patients with advanced RCC.07/12/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 12, 2017 Category: Urology & Nephrology Source Type: news

Europe Reaffirms Gadolinium Restriction in Scans Europe Reaffirms Gadolinium Restriction in Scans
After reexamination, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee has reaffirmed that there is evidence that the contrast agent is deposited in the brain.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 7, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

EMA and FDA propose new approach for Gaucher disease drug development
The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have   proposed   new approaches to the development of medicine to treat   Gaucher disease. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 4, 2017 Category: Pharmaceuticals Source Type: news

Sun Pharmaceutical signs agreement with Samsung BioLogics for psoriasis drug
The novel drug known as Tildrakizumab is currently under review by the US FDA and the European Medicines Agency (EMA). The value of the contract is about $55.5 million. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 4, 2017 Category: Pharmaceuticals Source Type: news

Roche ’s polatuzumab vedotin receives priority medicines scheme (PRIME) designation for treatment of the most common form of aggressive lymphoma
Roche today announced that the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) designation for the company ’s investigational medicine polatuzumab vedotin in combination with MabThera® (rituximab) and bendamustine for the treatment of people with relapsed or refractory diffuse large B cell lymphoma (DLBCL), the most common aggressive form of non-Hodgkin lymphoma. (Source: Roche Investor Update)
Source: Roche Investor Update - June 30, 2017 Category: Pharmaceuticals Source Type: news

QS Pharma receives EMA approval for medicinal products manufacturing
US-based pharmaceutical company QS Pharma has received approval from the European Medicines Agency (EMA) to produce certain medicinal products for commercial use in Europe. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 27, 2017 Category: Pharmaceuticals Source Type: news

Amber warning for the UK's access to new medicines post Brexit
(ecancermedicalscience) In an editorial to be published on Tuesday June 27, 2017 in the journal ecancermedicalscience, Anthony Hatswell of BresMed and University College London, explores the consequences of a British exit from the European Medicines Agency as a result of Brexit, and what this will mean for pharmaceutical regulation and future access to medicines for UK citizens. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 27, 2017 Category: Cancer & Oncology Source Type: news

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis
The European Medicines Agency ’ s Committee for Medicinal Products for Human Use recommends approval of cladribine to reduce relapses and delay disease progression in highly active relapsing MS.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 24, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

EU Regulators Limit Symbioflor 2 to Irritable Bowel Syndrome EU Regulators Limit Symbioflor 2 to Irritable Bowel Syndrome
The European Medicines Agency also directed the company that markets the probiotic to conduct a study on how well it treats variants of IBS.News Alerts (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - June 23, 2017 Category: Primary Care Tags: Gastroenterology News Alert Source Type: news